OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of no…
Biotechnology
FR, Nantes [HQ]
Ratios
12 Records · Starting from 2012Margins, Growth Rates In %
| Ratio | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||
| Gross Margin | - - | - - | - - | -225.00 | 95.82 | 100.00 | 99.98 | 99.97 | 100.01 | 100.00 | 100.00 | 100.00 | |
| Profit Margin | - - | - - | - - | -139,600.00 | 5,395.82 | -157.18 | 22.45 | -17.93 | -158.91 | -64.05 | -97.04 | -1,032.91 | |
| Operating Margin | - - | - - | - - | -135,500.00 | -148.04 | -188.94 | 19.82 | -19.50 | -237.44 | -83.53 | -131.34 | -1,452.85 | |
|
EPS Growth
|
- - | 81.78 | -997.56 | -63.89 | 379.66 | -144.24 | 147.95 | -188.57 | -241.94 | 12.26 | -3.23 | -22.92 | |
| EPS EUR | -18.00 | -3.28 | -36.00 | -59.00 | 165.00 | -73.00 | 35.00 | -31.00 | -106.00 | -93.00 | -96.00 | -118.00 | |
| Return on Assets (ROA) | -509.22 | -74.40 | -143.18 | -32.86 | 23.08 | -13.58 | 7.14 | -5.23 | -17.09 | -16.60 | -19.37 | -28.09 | |
| Return on Equity (ROE) | 226.86 | 28.94 | 353.05 | -38.57 | 32.03 | -18.94 | 8.89 | -7.95 | -27.03 | -35.45 | -54.57 | -100.80 | |
| Return on Invested Capital (ROIC) | -1,616.53 | -176.68 | -751.20 | -35.14 | -0.71 | -24.60 | 6.10 | -7.59 | -21.43 | -21.28 | -24.68 | -39.12 | |
| Solvency | |||||||||||||
| Equity Ratio | -200 | -200 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 294.68 | 341.37 | 59.50 | 5.77 | 1.99 | 6.32 | 5.80 | 11.33 | 17.76 | 32.67 | 44.95 | 52.22 | |
| Debt/Equity | -131.28 | -132.76 | -146.70 | 6.77 | 2.77 | 8.81 | 7.22 | 17.21 | 28.08 | 69.78 | 126.61 | 187.41 | |
| Debt/EBITDA | -44.99 | -346.80 | -372.22 | 156.96 | 2,848.04 | 38.08 | -103.02 | 313.63 | 41.05 | -18.35 | -93.62 | -93.92 | |
|
Debt/Capitalization
|
419.70 | 405.30 | 314.13 | 6.34 | 2.69 | 8.10 | 6.74 | 14.68 | 21.92 | 41.10 | 55.87 | 65.21 | |
| Long-Term Debt/Capitalization | 419.70 | 405.30 | 982.42 | 1.39 | 1.82 | 7.19 | 5.84 | 13.60 | 21.28 | 39.32 | 53.36 | 60.88 | |
| Interest Debt per Share EUR | 0.11 | 0.15 | 0.15 | 0.12 | 0.13 | 0.35 | 0.29 | 0.69 | 1.12 | 1.87 | 2.31 | 2.30 | |
| Debt Growth | - - | 38.03 | 2.70 | -16.81 | 82.04 | 173.82 | -8.70 | 157.42 | 69.97 | 90.29 | 20.63 | 2.25 | |
| Liquidity | |||||||||||||
| Current Ratio | 302.38 | 581.13 | 102.01 | 732.15 | 195.78 | 165.45 | 253.71 | 230.72 | 281.94 | 263.73 | 228.67 | 162.13 | |
| Quick Ratio | 302.38 | 581.13 | 102.01 | 713.28 | 195.78 | 165.45 | 253.71 | 230.72 | 281.94 | 263.73 | 228.67 | 162.13 | |
| Cash Ratio | 220.24 | 528.30 | 58.81 | 404.86 | 79.76 | 66.54 | 105.49 | 180.33 | 207.87 | 200.33 | 157.49 | 99.32 | |
| Operating Cash Flow Ratio | -1,600 | -400 | -100 | -200 | - - | - - | - - | - - | -100 | - - | -100 | -100 | |
| Turnover | |||||||||||||
| Inventory Turnover | - - | - - | - - | 2.99 | 1,600,000.00 | - - | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | 0.92 | 3.11 | 5,261.42 | 1,085.49 | 477.67 | 130.75 | 343.29 | 225.17 | 24.58 | |
| Payables Turnover | - - | - - | - - | 1.15 | 0.38 | - - | 0.06 | 0.19 | -0.01 | - - | - - | - - | |
|
Asset Turnover
|
- - | - - | - - | 0.02 | 0.43 | 8.64 | 31.80 | 29.20 | 10.76 | 25.91 | 19.97 | 2.72 | |
| Fixed Turnover | - - | - - | - - | 6.15 | 348.18 | 1,557.58 | 2,705.31 | 960.83 | 274.52 | 483.66 | 367.58 | 54.72 | |
| Coverage | |||||||||||||
| Interest Coverage | - - | - - | - - | -4,201.55 | -2,362.50 | -16,396.10 | 4,847.00 | -2,796.13 | -9,060.81 | -2,628.35 | -1,751.97 | -1,474.03 | |
| Asset Coverage | - - | - - | - - | 1,500 | 1,000 | 200 | 300 | 100 | 100 | - - | - - | - - | |
| Cash Flow Coverage (CFGR) | -167.63 | -20.58 | -164.43 | -470.82 | 38.34 | -163.68 | 24.15 | 89.10 | -113.69 | -29.91 | -44.29 | -46.21 | |
| EBITDA Coverage | - - | - - | - - | -4,100 | -1,900 | -16,200 | 4,900 | -2,500 | -8,700 | -2,300 | -1,400 | -1,300 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | 100 | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.76 | -0.31 | -3.47 | -6.96 | 21.48 | -18.28 | 10.41 | -8.44 | -14.78 | -9.03 | -14.42 | -27.47 | |
|
Price/Earnings (P/E)
|
-56.8324 | -319.0385 | -28.7871 | -14.3729 | 4.6548 | -5.4692 | 9.6099 | -11.8448 | -6.7655 | -11.0762 | -6.9371 | -3.6398 | |
| Price/Earnings Growth (PEG) | - - | 390.13 | -2.89 | -22.50 | -1.23 | 3.79 | -6.50 | 6.28 | -2.80 | 90.31 | -215.05 | -15.88 | |
|
Price/Book (P/B)
|
-12,892.78 | -9,231.44 | -10,163.31 | 554.42 | 149.08 | 103.60 | 85.43 | 94.20 | 182.90 | 392.62 | 378.54 | 366.88 | |
| Price/Tangible Book (P/TB) | -12,892.78 | -9,231.44 | -10,163.31 | 554.42 | 149.08 | 103.60 | 85.43 | 94.20 | 182.90 | 392.62 | 378.54 | 366.88 | |
| Price/Sales (P/S) | - - | - - | - - | 2,006,454.07 | 25,116.61 | 859.67 | 215.73 | 212.32 | 1,075.10 | 709.47 | 673.16 | 3,759.59 | |
|
Price/Cash Flow (P/CF)
|
-5,858.67 | -33,796.45 | -4,213.29 | -1,739.45 | 14,063.83 | -718.40 | 4,898.65 | 614.23 | -572.91 | -1,881.57 | -675.01 | -423.63 | |
| Price/Free CF (P/FCF) | -5,858.67 | -33,796.45 | -4,159.60 | -1,723.39 | 14,708.96 | -688.03 | 10,900.50 | 638.13 | -566.82 | -1,796.10 | -665.02 | -418.71 | |
| Price/Operating CF (P/OCF) | -5,858.67 | -33,796.45 | -4,213.29 | -1,739.45 | 14,063.83 | -718.40 | 4,898.65 | 614.23 | -572.91 | -1,881.57 | -675.01 | -423.63 |